Luspatercept
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
β-thalassemia
Conditions
β-thalassemia
Trial Timeline
Feb 26, 2026 → Apr 17, 2031
NCT ID
NCT07215975About Luspatercept
Luspatercept is a pre-clinical stage product being developed by Bristol Myers Squibb for β-thalassemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07215975. Target conditions include β-thalassemia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07215975 | Pre-clinical | Recruiting |
| NCT07073690 | Pre-clinical | Active |
| NCT06788691 | Phase 2 | Recruiting |
| NCT07075406 | Pre-clinical | Completed |
| NCT06596642 | Pre-clinical | Active |
| NCT06073860 | Pre-clinical | Recruiting |
| NCT06045689 | Phase 3 | Active |
| NCT05891249 | Approved | Active |
| NCT05732961 | Phase 2 | Recruiting |
Competing Products
8 competing products in β-thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| luspatercept | Merck | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 1 | 33 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Luspatercept | Bristol Myers Squibb | Pre-clinical | 22 |
| PTG-300 | Protagonist Therapeutics | Phase 2 | 49 |
| PTG-300 | Protagonist Therapeutics | Phase 2 | 49 |